GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » E10

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) E10 : $6.20 (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Taro Pharmaceutical Industries's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.540. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $6.20 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Taro Pharmaceutical Industries's average E10 Growth Rate was -8.70% per year. During the past 3 years, the average E10 Growth Rate was -5.40% per year. During the past 5 years, the average E10 Growth Rate was -1.00% per year. During the past 10 years, the average E10 Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Taro Pharmaceutical Industries was 60.50% per year. The lowest was -15.10% per year. And the median was 27.15% per year.

As of today (2024-05-17), Taro Pharmaceutical Industries's current stock price is $42.30. Taro Pharmaceutical Industries's E10 for the quarter that ended in Dec. 2023 was $6.20. Taro Pharmaceutical Industries's Shiller PE Ratio of today is 6.82.

During the past 13 years, the highest Shiller PE Ratio of Taro Pharmaceutical Industries was 58.09. The lowest was 3.59. And the median was 14.16.


Taro Pharmaceutical Industries E10 Historical Data

The historical data trend for Taro Pharmaceutical Industries's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries E10 Chart

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.59 8.01 6.97 7.14 6.78

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.79 6.78 6.71 6.51 6.20

Competitive Comparison of Taro Pharmaceutical Industries's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taro Pharmaceutical Industries's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's Shiller PE Ratio falls into.



Taro Pharmaceutical Industries E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Taro Pharmaceutical Industries's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.54/129.4194*129.4194
=0.540

Current CPI (Dec. 2023) = 129.4194.

Taro Pharmaceutical Industries Quarterly Data

per share eps CPI Adj_EPS
201403 2.100 99.695 2.726
201406 1.080 100.560 1.390
201409 3.350 100.428 4.317
201412 3.330 99.070 4.350
201503 3.560 99.621 4.625
201506 2.420 100.684 3.111
201509 3.110 100.392 4.009
201512 4.410 99.792 5.719
201603 2.680 100.470 3.452
201606 2.590 101.688 3.296
201609 3.000 101.861 3.812
201612 3.420 101.863 4.345
201703 2.050 102.862 2.579
201706 1.350 103.349 1.691
201709 1.300 104.136 1.616
201712 0.450 104.011 0.560
201803 2.170 105.290 2.667
201806 1.710 106.317 2.082
201809 1.600 106.507 1.944
201812 2.400 105.998 2.930
201903 1.520 107.251 1.834
201906 1.720 108.070 2.060
201909 1.460 108.329 1.744
201912 1.760 108.420 2.101
202003 1.420 108.902 1.688
202006 -11.370 108.767 -13.529
202009 1.180 109.815 1.391
202012 0.860 109.897 1.013
202103 -0.780 111.754 -0.903
202106 -0.500 114.631 -0.565
202109 0.620 115.734 0.693
202112 0.700 117.630 0.770
202203 0.730 121.301 0.779
202206 0.370 125.017 0.383
202209 -0.070 125.227 -0.072
202212 0.190 125.222 0.196
202303 0.180 127.348 0.183
202306 0.270 128.729 0.271
202309 0.230 129.860 0.229
202312 0.540 129.419 0.540

Add all the adjusted EPS together and divide 10 will get our e10.


Taro Pharmaceutical Industries  (NYSE:TARO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Taro Pharmaceutical Industries's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=42.30/6.2
=6.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Taro Pharmaceutical Industries was 58.09. The lowest was 3.59. And the median was 14.16.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Taro Pharmaceutical Industries E10 Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro to Announce Third Quarter Results on January 27, 2022

By Business Wire Business Wire 01-21-2022

Taro to Acquire Alchemee From Galderma

By Business Wire Business Wire 02-22-2022

Taro to Announce First Quarter Results on July 29, 2020

By Business Wire Business Wire 07-22-2020

Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

By Business Wire Business Wire 09-28-2020

Taro to Announce Full Year Results on May 19, 2021

By Business Wire Business Wire 05-12-2021

Taro Achieves Global Resolution of DOJ Antitrust Investigations

By Business Wire Business Wire 07-24-2020

Taro Appoints New Chief Financial Officer

By Business Wire Business Wire 12-01-2021

Taro to Announce Second Quarter Results on October 28, 2021

By Business Wire Business Wire 10-21-2021

Taro to Announce Full Year Results on May 26, 2022

By Business Wire Business Wire 05-21-2022